Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer
The US FDA will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival data from the Nova trial
-
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections
GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr
-
GSK announces update on US FDA regulatory review of daprodustat in anaemia of chronic kidney disease
GSK today announced that the US FDA will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review daprodustat
-
US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial
-
Statement: Zantac (ranitidine) U.S. litigation
Statement regarding U.S. Zantac (ranitidine) litigation
-
GSK completes acquisition of Affinivax, Inc.
GSK today announced it has completed the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge.
-
Statement: Zantac (ranitidine) litigation
Response to recent speculative commentary regarding U.S. Zantac litigation
-
GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
Insights revealed sustained decline of recommended adult immunizations, excluding flu vaccinations, across the US during the pandemic
-
GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis
-
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK begins shipping FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT
-
GSK completes acquisition of Sierra Oncology
A California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer
-
GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
Inaugural grant awarded to the HealthTree Foundation, a non-profit organization who will address disparities in care in multiple myeloma
-
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
GSK and Sanofi announce positive data from their vaccine trial
-
GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial.
-
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
-
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate
-
GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA
Learn about the abstracts we are presenting focusing on approved therapies, as well as investigational medicines.
-
Local budding biologists explore the past, present and future during GSK Science in the Summer™ in partnership with the Franklin Institute
Free summer STEM enrichment program allows students to take on the role of biologists
-
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Learn about our first quarter 2022 results
-
US Food and Drug Administration accepts New Drug Application for daprodustat
Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme
